---
document_datetime: 2025-10-29 12:42:29
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lazcluze-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lazcluze-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.4600169
conversion_datetime: 2025-12-20 00:53:07.855481
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lazcluze

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                         |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------|
| Variation type II /  | This was an application for a variation | 18/09/2025                          |                                             | SmPC and PL                      | SmPC new text Based on the results of a phase 2 |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000261993   | following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2, 4.4 and 4.8 of the SmPC for Rybrevant and Lazcluze in order to include updated information on enhanced dermatologic management regimen as prophylactic treatment to reduce the risk of dermatological toxicities during treatment, based on results from study 61186372NSC2007. Study 61186372NSC2007 (COCOON) is a Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR- mutated NSCLC treated first-line with amivantamab + lazertinib. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor corrections to the PI for Lazcluze and Rybrevant.   | study in patients treated with amivantamab in combination with lazertinib assessing the use of prophylactic therapy with an oral antibiotic, a topical antibiotic on the scalp, a moisturiser on the face and whole body and an antiseptic on hands and feet, recommendations on dermatologic management have been strenghten in sections 4.2 and 4.4 of the SmPC of both products. Prophylactic therapy with oral and topical antibiotics is recommended to reduce the risk and severity of skin and nail reactions in patients receiving amivantamab and lazertinib at treatment initiation. Non comedogenic skin moisturiser (ceramide based or other formulations that provide long lasting skin hydration and exclude drying agents are preferred) on the face and whole body (except scalp) and chlorhexidine solution to wash hands and feet are also recommended beginning on day1 and continued foe the duration of treatment. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| Variation type II / EMA/VR/0000253354   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to provide final Overall Survival (OS) data following Rybrevant extension of indication procedure (EMEA/H/C/005454/II/0013), and Lazcluze MAA approval (EMEA/H/C/006074/0000), and based on final results from study 73841937NSC3003 (MARIPOSA); this is a pivotal randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in   | 19/06/2025   |     | SmPC   | SmPC new text OS, intracranial ORR and DOR data were updated in section 5.1 of the SmPC based on final results from the Mariposa study (a pivotal randomized, open-label, Phase 3 study that compares the efficacy and safety of the combination of amivantamab and lazertinib (Arm A) versus osimertinib monotherapy (Arm B) and lazertinib monotherapy (Arm C) in participants with EGFRm NSCLC): The final analysis of OS demonstrated a statistically significant improvement in OS for Rybrevant in combination with lazertinib compared to Osimertinib and the intracranial ORR and DOR were updated. For more information, please refer to the Summary of Product Characteristics.   |
|-----------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000257464   | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 12/06/2025   | N/A |        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                                       | substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.II.b.1 Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - B.II.b.1.a Secondary packaging   |            |     |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000258318 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 11/04/2025 | N/A |

<div style=\"page-break-after: always\"></div>

| C.I.z - To provide and updated Environmental Risk Assessment Report (ERA).   |
|------------------------------------------------------------------------------|